The global Cutaneous T-cell Lymphoma (CTCL) market is witnessing significant growth due to increasing disease prevalence, particularly among older populations, and advancements in diagnostic ...

Only systemic treatment for relapsed or refractory (r/r) CTCL to target the IL-2 receptor on malignant T-cells and Tregs LYMPHIR is expected to launch within the next five months LYMPHIR's approval ...

Hodgkin’s lymphoma is rapidly expanding, driven by innovative clinical advancements and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, ...

Clinical trial findings showed an objective response rate of 36.2%, with 8.7% of patients having a complete response. The Food and Drug Administration (FDA) has approved Lymphir (denileukin ...

Hodgkin lymphoma and other malignancies that express the CD30 protein have been the scourge of oncologists for decades. For ...

Over the past decade, there has been a significant increase in the number of approved drugs for treating lymphoma. Before the ...

Initiating first-in-human Phase 1 trial in H1 of 2024 PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...